NASDAQ
ALZN

Alzamend Neuro Inc

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Alzamend Neuro Inc Stock Price

Vitals

Today's Low:
$0.23
Today's High:
$0.25
Open Price:
$0.23
52W Low:
$0.49
52W High:
$1.5
Prev. Close:
$0.228
Volume:
208608

Company Statistics

Market Cap.:
$52.55 million
Book Value:
0.092
Revenue TTM:
$0
Operating Margin TTM:
0%
Gross Profit TTM:
$0
Profit Margin:
0%
Return on Assets TTM:
-63.04%
Return on Equity TTM:
-115.43%

Company Profile

Alzamend Neuro Inc had its IPO on 2021-06-15 under the ticker symbol ALZN.

The company operates in the Healthcare sector and Biotechnology industry. Alzamend Neuro Inc has a staff strength of 4 employees.

Stock update

Shares of Alzamend Neuro Inc opened at $0.23 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $0.23 - $0.25, and closed at $0.23.

This is a +1.32% increase from the previous day's closing price.

A total volume of 208,608 shares were traded at the close of the day’s session.

In the last one week, shares of Alzamend Neuro Inc have slipped by -16.3%.

Alzamend Neuro Inc's Key Ratios

Alzamend Neuro Inc has a market cap of $52.55 million, indicating a price to book ratio of 11.6318 and a price to sales ratio of 0.

In the last 12-months Alzamend Neuro Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-12315986. The EBITDA ratio measures Alzamend Neuro Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Alzamend Neuro Inc’s operating margin was 0% while its return on assets stood at -63.04% with a return of equity of -115.43%.

In Q3.3333333333333, Alzamend Neuro Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Alzamend Neuro Inc’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG

Its diluted EPS in the last 12-months stands at $-0.13 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Alzamend Neuro Inc’s profitability.

Alzamend Neuro Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -7.0897. Its price to sales ratio in the trailing 12-months stood at 0.

Alzamend Neuro Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$10.42 million
Total Liabilities
$1.64 million
Operating Cash Flow
$0
Capital Expenditure
$0
Dividend Payout Ratio
0%

Alzamend Neuro Inc ended 2024 with $10.42 million in total assets and $0 in total liabilities. Its intangible assets were valued at $10.42 million while shareholder equity stood at $8.79 million.

Alzamend Neuro Inc ended 2024 with $0 in deferred long-term liabilities, $1.64 million in other current liabilities, 9549.00 in common stock, $-35341560.00 in retained earnings and $0 in goodwill. Its cash balance stood at $9.18 million and cash and short-term investments were $9.18 million. The company’s total short-term debt was $0 while long-term debt stood at $0.

Alzamend Neuro Inc’s total current assets stands at $10.33 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $648119.00 and inventory worth $0.

In 2024, Alzamend Neuro Inc's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, Alzamend Neuro Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$0.23
52-Week High
$1.5
52-Week Low
$0.49
Analyst Target Price
$7

Alzamend Neuro Inc stock is currently trading at $0.23 per share. It touched a 52-week high of $1.5 and a 52-week low of $1.5. Analysts tracking the stock have a 12-month average target price of $7.

Its 50-day moving average was $0.39 and 200-day moving average was $0.57 The short ratio stood at 3.23 indicating a short percent outstanding of 0%.

Around 4166.5% of the company’s stock are held by insiders while 723.6% are held by institutions.

Frequently Asked Questions About Alzamend Neuro Inc

The stock symbol (also called stock or share ticker) of Alzamend Neuro Inc is ALZN

The IPO of Alzamend Neuro Inc took place on 2021-06-15

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$747.55
-3.35
-0.45%
Viatris Inc (VTRS)
$9.87
-0.14
-1.4%
$1.58
-0.08
-4.72%
$4.94
-0.48
-8.86%
$0.08
0
+1.43%
Posera Ltd (PRRSF)
$0.14
0.02
+12.82%
$25.53
1.21
+4.98%
$0.01
-0
-18.92%
$201.45
-12.25
-5.73%
$0.36
-0.02
-6.24%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company’s pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer’s, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and AL002 that completed preclinical stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient’s immunological system to combat Alzheimer’s disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

Address

3500 Lenox Road NE, Atlanta, GA, United States, 30326